Literature DB >> 9675319

Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease.

M Hashimoto1, L J Hsu, A Sisk, Y Xia, A Takeda, M Sundsmo, E Masliah.   

Abstract

The precursor of non-amyloid beta protein component of Alzheimer's disease amyloid (NACP/alpha-synuclein) is aggregated and fibrillated under certain conditions, i.e., increasing time lag, high temperature and low pH. These in vitro aggregates form Thioflavine-S-positive filamentous structures, reminiscent of amyloid-like fibrils. Since some Lewy bodies in Parkinson's disease display Thioflavine-S reactivity, our results may suggest that amyloidogenic properties of NACP/alpha-synuclein may play a crucial role in pathogenesis of disorders with Lewy bodies such as Parkinson's disease. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9675319     DOI： 10.1016/s0006-8993(98)00514-9

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  70 in total

1.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Conformational characterization of oligomeric intermediates and aggregates in beta-lactoglobulin heat aggregation.

Authors:  R Carrotta; R Bauer; R Waninge; C Rischel
Journal:  Protein Sci       Date:  2001-07       Impact factor: 6.725

3.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

4.  alpha-synuclein promotes mitochondrial deficit and oxidative stress.

Authors:  L J Hsu; Y Sagara; A Arroyo; E Rockenstein; A Sisk; M Mallory; J Wong; T Takenouchi; M Hashimoto; E Masliah
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

5.  Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease.

Authors:  Kunikazu Tanji; Fumiaki Mori; Katsumi Kito; Akiyoshi Kakita; Junsei Mimura; Ken Itoh; Hitoshi Takahashi; Tetsu Kamitani; Koichi Wakabayashi
Journal:  J Neuropathol Exp Neurol       Date:  2011-10       Impact factor: 3.685

Review 6.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

7.  Synuclein expression in the lizard Anolis carolinensis.

Authors:  Mattia Toni; Carla Cioni; Federica De Angelis; Maria Carmela Bonaccorsi di Patti
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2016-07-08       Impact factor: 1.836

8.  Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein.

Authors:  Robert Bussell; Trudy Fiona Ramlall; David Eliezer
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

Review 9.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 10.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.